Proliferation- and Apoptosis-related Proteins in Intracranial Ependymomas: an Immunohistochemical Analysis

Overview

Journal J Neurooncol

Publisher Springer

Date 2002 Apr 13

PMID 11949823

Citations 16

Authors

M J T Verstegen

D Troost S Leenstra

D A Bosch

Affiliations

Soon will be listed here.

Abstract

Unlabelled: As the value of grading of ependymomas is currently debated we studied the expression of proliferation- and apoptosis-related proteins in these tumors as these mechanisms both are suggested to be important in tumor growth. We characterized the immunohistochemical expression of p53, Mdm2, Bcl-2, and Bax in 51 intracranial ependymomas. We also assessed the apoptosis- and proliferation-index, measured by MIB-1, PCNA-immunohistochemistry, and analyzed the clinical parameters. Of all used antibodies, the correlation with survival and the correlation among ordered categories was assessed. None of the analyzed immunohistochemical variables were significantly correlated with tumor grade. On the other hand, PCNA, MIB-1, and p53 were significantly related to the survival of the patient. In multivariate analysis, p53 was the only independent predictive variable (p = 0.0132).

Conclusion: The strongest predictors of survival in univariate analysis were the expression of PCNA, MIB-1 and p53. In multivariate analysis a p53 expression > 1% showed to be significantly related with a worse survival. The predicting value of p53 expression has to be confirmed by others before solid conclusions can be made. Apoptosis seems not to be an important mechanism in tumor growth in ependymomas. The expression of Mdm2, Bcl-2, and Bax were not related to survival.

Citing Articles

Molecular subtyping of ependymoma and prognostic impact of Ki-67.

Lim K, Lee K, Shim Y, Park J, Kim H, Kang J Brain Tumor Pathol. 2021; 39(1):1-13.

PMID: 34812989 PMC: 8752536. DOI: 10.1007/s10014-021-00417-y.

Identification of biomarkers and construction of a microRNA-mRNA regulatory network for ependymoma using integrated bioinformatics analysis.

Yang B, Dai J, Pan Y, Ma Y, Chu S Oncol Lett. 2019; 18(6):6079-6089.

PMID: 31788082 PMC: 6865127. DOI: 10.3892/ol.2019.10941.

Factors associated with postoperative outcomes in patients with intramedullary Grade II ependymomas: A Systematic review and meta-analysis.

Sun X, Wang W, Zhang T, Kong C, Sun S, Guo M Medicine (Baltimore). 2019; 98(25):e16185.

PMID: 31232977 PMC: 6637017. DOI: 10.1097/MD.0000000000016185.

P53 and Ki-67 Expression in Primary Pediatric Brain Tumors: Does it Correlate with Presentation, Histological Grade, and Outcome?.

Sharma V, Shoaib Y, Gupta L, Dagar A Asian J Neurosurg. 2018; 13(4):1026-1032.

PMID: 30459861 PMC: 6208193. DOI: 10.4103/ajns.AJNS_69_17.

A De Novo Mouse Model of C11orf95-RELA Fusion-Driven Ependymoma Identifies Driver Functions in Addition to NF-κB.

Ozawa T, Arora S, Szulzewsky F, Juric-Sekhar G, Miyajima Y, Bolouri H Cell Rep. 2018; 23(13):3787-3797.

PMID: 29949764 PMC: 6411037. DOI: 10.1016/j.celrep.2018.04.099.

References

Mork S, LOKEN A . Ependymoma: a follow-up study of 101 cases. Cancer. 1977; 40(2):907-15. DOI: 10.1002/1097-0142(197708)40:2<907::aid-cncr2820400247>3.0.co;2-2. View

Schiffer D, Cavalla P, Migheli A, Giordana M . Bcl-2 distribution in neuroepithelial tumors: an immunohistochemical study. J Neurooncol. 1996; 27(2):101-9. DOI: 10.1007/BF00177472. View

Kleihues P, Burger P, Scheithauer B . The new WHO classification of brain tumours. Brain Pathol. 1993; 3(3):255-68. DOI: 10.1111/j.1750-3639.1993.tb00752.x. View

Schiffer D, Chio A, CRAVIOTO H, Giordana M, Migheli A, Soffietti R . Ependymoma: internal correlations among pathological signs: the anaplastic variant. Neurosurgery. 1991; 29(2):206-10. View

Reardon D, Entrekin R, Sublett J, Ragsdale S, Li H, Boyett J . Chromosome arm 6q loss is the most common recurrent autosomal alteration detected in primary pediatric ependymoma. Genes Chromosomes Cancer. 1999; 24(3):230-7. DOI: 10.1002/(sici)1098-2264(199903)24:3<230::aid-gcc8>3.0.co;2-c. View

Capoulade C, Bressac-de Paillerets B, Lefrere I, Ronsin M, Feunteun J, Tursz T . Overexpression of MDM2, due to enhanced translation, results in inactivation of wild-type p53 in Burkitt's lymphoma cells. Oncogene. 1998; 16(12):1603-10. DOI: 10.1038/sj.onc.1201702. View

Schiffer D, Cavalla P, Migheli A, Chio A, Giordana M, Marino S . Apoptosis and cell proliferation in human neuroepithelial tumors. Neurosci Lett. 1995; 195(2):81-4. DOI: 10.1016/0304-3940(95)11784-t. View

Neumann E, Kalousek D, NORMAN M, Steinbok P, Cochrane D, Goddard K . Cytogenetic analysis of 109 pediatric central nervous system tumors. Cancer Genet Cytogenet. 1993; 71(1):40-9. DOI: 10.1016/0165-4608(93)90200-6. View

Wang Y, Szekely L, Okan I, Klein G, Wiman K . Wild-type p53-triggered apoptosis is inhibited by bcl-2 in a v-myc-induced T-cell lymphoma line. Oncogene. 1993; 8(12):3427-31. View

10.

Vanuytsel L, Bessell E, Ashley S, BLOOM H, Brada M . Intracranial ependymoma: long-term results of a policy of surgery and radiotherapy. Int J Radiat Oncol Biol Phys. 1992; 23(2):313-9. DOI: 10.1016/0360-3016(92)90747-6. View

11.

Leach F, Tokino T, Meltzer P, Burrell M, Oliner J, Smith S . p53 Mutation and MDM2 amplification in human soft tissue sarcomas. Cancer Res. 1993; 53(10 Suppl):2231-4. View

12.

Korkolopoulou P, Christodoulou P, Kouzelis K, Hadjiyannakis M, Priftis A, Stamoulis G . MDM2 and p53 expression in gliomas: a multivariate survival analysis including proliferation markers and epidermal growth factor receptor. Br J Cancer. 1997; 75(9):1269-78. PMC: 2228241. DOI: 10.1038/bjc.1997.216. View

13.

Blok P, Craanen M, Dekker W, Offerhaus G, Tytgat G . No evidence for functional inactivation of wild-type p53 protein by MDM2 overexpression in gastric carcinogenesis. J Pathol. 1999; 186(1):36-40. DOI: 10.1002/(SICI)1096-9896(199809)186:1<36::AID-PATH150>3.0.CO;2-R. View

14.

Marchetti A, Buttitta F, Girlando S, Dalla Palma P, Pellegrini S, Fina P . mdm2 gene alterations and mdm2 protein expression in breast carcinomas. J Pathol. 1995; 175(1):31-8. DOI: 10.1002/path.1711750106. View

15.

Fink K, Rushing E, Schold Jr S, Nisen P . Infrequency of p53 gene mutations in ependymomas. J Neurooncol. 1996; 27(2):111-5. DOI: 10.1007/BF00177473. View

16.

Miyashita T, Krajewski S, Krajewska M, Wang H, Lin H, Liebermann D . Tumor suppressor p53 is a regulator of bcl-2 and bax gene expression in vitro and in vivo. Oncogene. 1994; 9(6):1799-805. View

17.

Figarella-Branger D, Civatte M, Gouvernet J, Gambarelli D, Gentet J, Lena G . Prognostic factors in intracranial ependymomas in children. J Neurosurg. 2000; 93(4):605-13. DOI: 10.3171/jns.2000.93.4.0605. View

18.

RITTER A, Hess K, McLendon R, Langford L . Ependymomas: MIB-1 proliferation index and survival. J Neurooncol. 1999; 40(1):51-7. DOI: 10.1023/a:1006082622699. View

19.

Ross G, Rubinstein L . Lack of histopathological correlation of malignant ependymomas with postoperative survival. J Neurosurg. 1989; 70(1):31-6. DOI: 10.3171/jns.1989.70.1.0031. View

20.

Biernat W, Kleihues P, Yonekawa Y, Ohgaki H . Amplification and overexpression of MDM2 in primary (de novo) glioblastomas. J Neuropathol Exp Neurol. 1997; 56(2):180-5. DOI: 10.1097/00005072-199702000-00009. View